Q-Med Board Endorses Galderma's Sweetened Bid

Law360, New York (February 10, 2011, 3:52 PM EST) -- Q-Med AB's board of directors is urging reluctant shareholders to accept Galderma Pharma SA's latest takeover bid, which the skin care company has boosted from $978 million to $1.2 billion in an attempt to woo the implant maker.

Q-Med's board issued a statement Thursday saying it unanimously recommended Galderma's 79 kronor ($12.22) per share bid, adding that the offer is “fair from a financial point of view for the shareholders in Q-Med.”

The offer comes just after Galderma said Tuesday that it lacked interest among Q-Med...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.